Leqembi Injection, Solution
Product Images NDC 62856-215

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Leqembi (NDC 62856-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Reduction In Brain Amyloid Beta Plaque (adjusted Mean Change From Baseline In Amyloid Beta Pet Composite, Suvr And Centiloids) In Study 1 (Lecanemab Autoinjector 01)

A line graph comparing adjusted mean change from baseline over time between placebo and 10 mg/kg lecanemab every two weeks. The x-axis shows analysis visits at baseline, week 53, and week 79, with patient numbers listed below. The y-axes show adjusted mean changes from baseline with standard error for SUVR (left) and centiloid (right). The graph indicates a statistically significant reduction for the lecanemab group at weeks 53 and 79 compared to placebo (p<0.001).*

FDA Label Image

Figure 2: Adjusted Mean Change From Baseline In Cdr-sb In Study 2 (Lecanemab Autoinjector 02)

A line graph showing the adjusted mean change from baseline over 18 months in two groups: Placebo and 10 mg/kg of lecanemab administered every two weeks. The y-axis represents change from baseline, and the x-axis represents visit months from 0 to 18. The graph shows a greater decline in the placebo group compared to the treatment group, with data points and error bars included. Sample sizes for each group at various months are listed below the x-axis. Statistical significance (p < 0.0001) is indicated.*

FDA Label Image

360 mg Autoinjector (Lecanemab Autoinjector 03)

An instructional diagram showing a syringe labeled LEQEMBI before and after use. Before use, the syringe has a clear cap and needle cover with a viewing window and an expiration date label. After use, the syringe features a purple plunger rod, a magenta needle cover with the needle inside, and a detached clear cap.*

FDA Label Image

Gather Supplies (Lecanemab Autoinjector 04)

An instructional illustration showing included and not included supplies for LEQEMBI autoinjector use. The included item is one LEQEMBI IQLIK autoinjector. Supplies not included are alcohol wipe, cotton ball or gauze, sharps disposal container, and adhesive bandage.*

FDA Label Image

Step 1 (Lecanemab Autoinjector 05)

An instructional illustration showing a clock indicating 20 minutes and a boxed product with a close-up of a label area for date coding in the format YYYY-MM. The image suggests checking or waiting 20 minutes related to the product's use or preparation.*

FDA Label Image

Step 2 (Lecanemab Autoinjector 06)

An instructional illustration showing hands holding a syringe labeled LEQEMBI. The diagram highlights a viewing window on the syringe where a date code (formatted as YYYY-MM) is visible for checking.*

FDA Label Image

A Picture Containing Linedrawingdescription Automatically Generated (Lecanemab Autoinjector 07)

An instructional illustration showing two hands being washed under running water with soap suds, indicating proper handwashing technique.*

FDA Label Image

Step 4 (Lecanemab Autoinjector 08)

Illustration showing recommended injection sites for LEQEMBI (lecanemab) intravenous injection. The front view highlights self or caregiver injection sites including the abdomen and thighs. The back view shows caregiver-only sites on the upper arms.*

FDA Label Image

Step 5 (Lecanemab Autoinjector 09)

An instructional line drawing showing a hand applying a square adhesive patch to the skin on the inner forearm, commonly illustrating a step in preparing or securing a treatment site for injection or infusion.*

FDA Label Image

Step 6 (Lecanemab Autoinjector 0a)

An instructional illustration showing hands removing a clear cap from the tip of a pen-like injection device. This diagram likely demonstrates preparation steps for administering an injection solution, possibly related to LEQEMBI (lecanemab) given the product context.*

FDA Label Image

A Picture Containing Linedrawingdescription Automatically Generated (Lecanemab Autoinjector 0b)

An instructional illustration showing a hand holding a syringe above a sharps disposal container, demonstrating the proper disposal of the syringe after use.*

FDA Label Image

Step 8 (Lecanemab Autoinjector 0c)

An instructional illustration showing a hand holding an injection device vertically at a 90-degree angle to a flat surface, demonstrating the correct positioning for use of the product.*

FDA Label Image

Step 9 (Lecanemab Autoinjector 0d)

An instructional diagram showing a hand holding a device vertically, pressing down to administer an injection. The image includes text arrows indicating 'push down' and 'first click,' demonstrating the injection step.*

FDA Label Image

Step 10 (Lecanemab Autoinjector 0e)

An instructional illustration showing a hand holding a device in an upright position with a visible purple window. The diagram indicates to keep holding the device for 10 seconds after the first click, followed by a second click. This likely demonstrates the correct usage steps for administering a drug injection.*

FDA Label Image

Step 11 (Lecanemab Autoinjector 0f)

An instructional illustration showing a hand holding a vertical injectable pen or syringe against a surface, with an arrow pointing downward and the words "keep holding," indicating a step in the administration process of the medication.*

FDA Label Image

Step 12 (Lecanemab Autoinjector 10)

Illustration showing a hand holding an injection device at a 90-degree angle to the skin surface. An arrow indicates the direction of insertion for administering the solution, demonstrating the proper intradermal or subcutaneous injection technique.*

FDA Label Image

Step 13 (Lecanemab Autoinjector 11)

An instructional illustration showing a hand holding a small rectangular wipe or pad, demonstrating its use on a surface, likely to clean or prepare the area. No text or product branding is visible.*

FDA Label Image

Diagramdescription Automatically Generated With Medium Confidence (Lecanemab Autoinjector 12)

An instructional illustration showing a hand holding a used injection device being disposed of into a sharps container. The image depicts proper disposal practices for injection equipment associated with LEQEMBI, an intravenous injection solution of lecanemab.*

FDA Label Image

Before Use And After Use (Lecanemab Autoinjector 13)

An instructional diagram showing the LEQEMBI injection pen before and after use. The 'Before use' image highlights a clear cap and needle cover, a viewing window, and a label expiration date area. The 'After use' image shows a removed needle cover revealing a yellow plunger rod and confirms the presence of a clear cap and light grey needle cover with needle inside.*

FDA Label Image

Included Supplies (Lecanemab Autoinjector 14)

An instructional illustration showing included and not included supplies for LEQEMBI. Included are 2 LEQEMBI IQLIK autoinjectors. Supplies not included are alcohol wipe, cotton ball or gauze, sharps disposal container, and adhesive bandage.*

FDA Label Image

Step 1 (Lecanemab Autoinjector 15)

An instructional diagram showing a 20-minute timer alongside a depiction of a box with an arrow pointing to a label area, likely indicating labeling or timing instructions related to the product packaging.*

FDA Label Image

Step 2 (Lecanemab Autoinjector 16)

An instructional illustration showing a person holding a test strip or similar device with a labeled 'Check Viewing Window.' A zoomed-in inset highlights the viewing window area with sample placeholder text 'YYYY-MMM.' The diagram focuses on how to check the viewing window on the device.*

FDA Label Image

Step 3 (Lecanemab Autoinjector 17)

An instructional illustration showing two hands being washed under running water with soap bubbles, demonstrating proper handwashing technique.*

FDA Label Image

Step 4 (Lecanemab Autoinjector 18)

An instructional diagram showing recommended injection sites for LEQEMBI (lecanemab) intravenous injection solution. Front view indicates self or caregiver injection sites on the abdomen and thighs. Back view shows caregiver-only injection sites on the upper arms.*

FDA Label Image

Step 5 (Lecanemab Autoinjector 19)

An illustration showing a hand holding a wipe or cloth, appearing to clean or prepare an area on the forearm. The image likely depicts aseptic technique or skin preparation prior to an injection or intravenous administration.*

FDA Label Image

Step 6 (Lecanemab Autoinjector 1a)

An instructional illustration showing a person's hands holding a LEQEMBI injection pen and a clear cap. The image demonstrates the removal of the clear cap from the injection pen before use.*

FDA Label Image

Step 7 (Lecanemab Autoinjector 1b)

An instructional illustration showing a hand disposing of a small vial or container into a medical sharps disposal container. This image likely demonstrates proper disposal procedures for used injection materials related to LEQEMBI (lecanemab) intravenous injection.*

FDA Label Image

Step 8 (Lecanemab Autoinjector 1c)

An instructional illustration showing a hand holding an injection device at a 90-degree angle to the skin surface. The image demonstrates the proper technique for administering an injection, likely intravenous, in a clear step-by-step visual format.*

FDA Label Image

Step 9 (Lecanemab Autoinjector 1d)

An instructional illustration showing a hand holding a pen-like device positioned against skin. Arrows and text indicate to push down until the first click is heard, demonstrating the correct injection technique for administering a solution.*

FDA Label Image

Step 10 (Lecanemab Autoinjector 1e)

An instructional illustration showing a hand holding an injection device with a visible window containing orange liquid. The image instructs to keep holding the device for 10 seconds after a second click, emphasizing proper use for intravenous injection administration.*

FDA Label Image

Step 11 (Lecanemab Autoinjector 1f)

An instructional illustration showing a hand holding a device upright with the instruction 'keep holding' and a downward arrow indicating direction. The device appears to have a window or indicator area highlighted in orange near the bottom.*

FDA Label Image

Step 12 (Lecanemab Autoinjector 20)

Illustration showing a hand holding an injection pen or device at a 90-degree angle to the skin surface, indicating the proper angle for intravenous administration of an injection solution.*

FDA Label Image

Step 13 (Lecanemab Autoinjector 21)

An instructional line drawing showing a hand using a cloth or wipe to clean or prepare an area on the forearm, likely demonstrating skin preparation prior to intravenous injection.*

FDA Label Image

Step 14 (Lecanemab Autoinjector 22)

An illustration showing a hand holding a medical device or pen injector over a container, possibly a sharps disposal container, indicating the action of disposing the device. The image is instructional without text.*

FDA Label Image

Principal Display Panelndc 62856-215-01leqembi® (lecanemab-irmb) Injection500 mg/5 mL(100 mg/ mL)single-dose Vial (Lecanemab Autoinjector 23)

Carton packaging label for LEQEMBI injection by Eisai Inc. The product contains lecanemab at a strength of 500 mg/5 mL (100 mg/mL) as an intravenous solution. The label includes dosing instructions, storage information, barcode, and a QR code, all printed on a predominantly white and maroon background.*

FDA Label Image

Principal Display Panelndc 62856-215-01leqembi® (lecanemab-irmb) Injection500 mg/5 mL(100 mg/ mL)single-dose Vial (Lecanemab Autoinjector 24)

LEQEMBI (lecanemab-irmb) Injection 500 mg/5 mL (100 mg/mL) single-dose vial label. The label indicates it is for intravenous infusion only, requires dilution prior to use, and advises to see prescribing information for dosage. Manufactured by Eisai Inc. with US License No. 1862.*

FDA Label Image

Principal Display Panelndc 62856-212-01leqembi® (lecanemab-irmb) Injection200 mg/2 mL(100 mg/ mL)1 Vial Per Carton (Lecanemab Autoinjector 25)

Packaging label for LEQEMBI (lecanemab) Injection, 200 mg/2 mL (100 mg/mL) intravenous solution by Eisai Inc. The label shows dosage strength, administration route, storage instructions, and manufacturer details, along with barcodes and a QR code for product information. It is intended for human prescription drug use with a single dose vial per carton.*

FDA Label Image

Principal Display Panelndc 62856-212-01leqembi® (lecanemab-irmb) Injection200 mg/2 mL(100 mg/ mL)1 Vial Per Carton (Lecanemab Autoinjector 26)

Label for LEQEMBI (lecanemab-irmb) Injection, solution for intravenous infusion, showing 200 mg per 2 mL (100 mg/mL) strength in a single-dose vial. The label includes dosage instructions to see prescribing information, manufacturer Eisai Inc., and US license number 1862.*

FDA Label Image

Principal Display Panelndc 62856-220-01leqembi® Lqlik (lecanemab-irmb) Injection360 mg/1.8 mL (Lecanemab Autoinjector 27)

LEQEMBI IQLIK (lecanemab-irmb) Injection 360 mg/1.8 mL prefilled autoinjector for subcutaneous injection only. The packaging includes dosing and storage instructions, manufacturer details: Eisai Inc., and Biogen, with a QR code for more information. The label emphasizes single-dose use and discarding after use.*

FDA Label Image

Principal Display Panelndc 62856-220-10rx Onlyleqembi® Lqlik (lecanemab-irmb) Injection360 mg/1.8 mL (Lecanemab Autoinjector 28)

Label for LEQEMBI IQLIK (lecanemab-irmb) injection, detailing a single-dose prefilled autoinjector with a strength of 360 mg/1.8 mL for subcutaneous injection only. Manufactured by Eisai Inc. and Biogen Inc., with storage instructions to refrigerate at 2°C to 8°C and warnings against freezing or shaking. The label includes manufacturer location, barcode area, and placeholders for lot and expiration date.*

FDA Label Image

Principal Display Panelndc 62856-215-01leqembi® (lecanemab-irmb) Injection500 mg/5 mL(100 mg/ mL)single-dose Vial (Lecanemab Autoinjector 29)

LEQEMBI injection label and carton design for 500 mg/5 mL (100 mg/mL) solution. The label includes the proprietary name LEQEMBI with the generic name lecanemab-imb, dosage form injection, concentration 100 mg/mL, and instructions for intravenous infusion. The label also shows the Eisai Inc. and Biogen logos, barcodes, and storage instructions to refrigerate the product at 2 to 8 °C. The packaging indicates it is for single-dose vial use and provides disposal instructions for unused portions.*

FDA Label Image

Principal Display Panelndc 62856-212-01leqembi® (lecanemab-irmb) Injection200 mg/2 mL(100 mg/ mL)1 Vial Per Carton (Lecanemab Autoinjector 2a)

Packaging label for LEQEMBI injection, containing lecanemab at a strength of 200 mg per 2 mL (100 mg/mL). This carton design is marked for intravenous use and labeled for prescription use only. The labeler is Eisai Inc., and the label includes dosing and handling instructions, lot and expiration date areas, and product identification details.*

FDA Label Image

Ndc 62856-222-10leqembi Iqik® (lecanemab-irmb) Injectionfor Subcutaneous Injection Only250 mg/1.25 mLsingle-dose Prefilled Autoinjector. (Lecanemab Autoinjector 2b)

Label for LEQEMBI IQLIK (lecanemab-irmb) injection, 250 mg per 1.25 mL, single-dose prefilled autoinjector. For subcutaneous injection only. Manufactured by Eisai Inc. and Biogen Inc., Nutley, NJ. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F) and to protect from light; do not freeze or shake. Includes NDC 62856-222-10 and Rx Only designation.*

FDA Label Image

Ndc 62856-222-02rx Onlyleqembi Iqik® (lecanemab-irmb) Injectionfor Subcutaneous Injection Only250 mg/1.25 mL2 Single-dose Prefilled Autoinjectors. Discard After Use. (Lecanemab Autoinjector 2c)

LEQEMBI IQLIK (lecanemab-irmb) Injection 250 mg/1.25 mL carton label for subcutaneous injection. The carton includes 2 single-dose prefilled autoinjectors, with instructions for use and storage at 2°C to 8°C. Manufactured by Eisai Inc., it features full prescribing information and medication guide notices on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.